Why did the neurologist switch the anticonvulsant from phenytoin to divalproex sodium?

• A. To reduce possible side effects and increase medication compliance.
• B. To lower the cost of treatment.
• C. To avoid monitoring requirements altogether.
• D. To shorten the hospital stay.

Answer: (A)

The main idea is that selecting an anticonvulsant should balance seizure control with tolerability and how easy it is for the patient to stay on the medication. Phenytoin often causes many side effects—like gum overgrowth, excessive hair growth, dizziness or drowsiness, double vision, and various skin reactions—and it interacts with many other drugs because it strongly induces liver enzymes. It also requires careful, sometimes frequent, monitoring of drug levels. All of this can make the treatment harder to tolerate and harder to keep up with, which hurts adherence.

Switching to divalproex sodium (valproate) can lessen these issues for many patients. While valproate has its own risks (notably liver toxicity and teratogenicity), its side-effect profile is often more tolerable for some individuals, and the regimen can be simpler with fewer drug interactions and less intensive level monitoring in everyday practice. That combination—fewer adverse effects and a regimen that patients find easier to follow—primarily supports better compliance and, in turn, ongoing seizure control.

Cost or the idea of eliminating monitoring altogether aren’t main drivers, and changing the drug isn’t guaranteed to shorten a hospital stay.